A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer
一项针对晚期或转移性胃癌患者的II期研究，评估每两周一次的剂量强化口服卡培他滨联合伊立替康（bXELIRI）方案的疗效。
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6603752
Oh, S C; Sur, H Y; Sung, H J; Choi, I K; Park, S S; Seo, J H; Jeen, Y T; Chun, H J; Shin, S W; Mok, Y J; Kim, J S; Kim, Y H
